Autolus Current Deferred Revenue from 2010 to 2024
| AUTL Stock | USD 2.98 0.04 1.36% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter -4.6 M | Current Value -4.4 M | Quarterly Volatility 11 M |
Check Autolus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Autolus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 47.3 M, Selling General Administrative of 25.9 M or Total Revenue of 2 M, as well as many indicators such as Price To Sales Ratio of 981, Dividend Yield of 0.0 or PTB Ratio of 6.27. Autolus financial statements analysis is a perfect complement when working with Autolus Therapeutics Valuation or Volatility modules.
Autolus | Current Deferred Revenue |
Latest Autolus Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Autolus Therapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Autolus Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Autolus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Autolus Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 16,227,815 | |
| Coefficient Of Variation | 67.75 | |
| Mean Deviation | 8,385,097 | |
| Median | 20,682,000 | |
| Standard Deviation | 10,994,783 | |
| Sample Variance | 120.9T | |
| Range | 32.4M | |
| R-Value | (0.62) | |
| Mean Square Error | 80.4T | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | (1,520,029) | |
| Total Sum of Squares | 1692.4T |
Autolus Current Deferred Revenue History
About Autolus Therapeutics Financial Statements
Autolus Therapeutics investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how Autolus Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -4.6 M | -4.4 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Autolus Therapeutics Correlation against competitors. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share 0.043 | Quarterly Revenue Growth 6.81 | Return On Assets (0.22) | Return On Equity (0.82) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.